Status:
TERMINATED
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Lead Sponsor:
University of Calgary
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthra...
Detailed Description
Study Focus and Design: Breast cancer is one of the leading cancers among white and African American women; its incidence has increased from one in 20 in 1960 to one in eight today ARMSTRONG 2000. In...
Eligibility Criteria
Inclusion
- First-time diagnosis of breast cancer
- Planned chemotherapy with anthracyclines and / or Trastuzumab
- Ability to give informed consent
Exclusion
- Contra-indications for CMR study (e.g. implanted pacemaker / ICD; severe renal impairment (GFR\< 35 ml/min); severe claustrophobia)
- Previous history of non-ischemic cardiomyopathies or myocardial inflammation
- Inability to give informed consent
- Concomitant drug abuse (e.g. cocaine)
- Expected life expectancy \< 6 months
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2011
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00679874
Start Date
May 1 2008
End Date
September 1 2011
Last Update
October 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary, Dept. of Cardiac Sciences and Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 2T9